The Retina Foundation is pleased to share 20/20 video updates as we continue to move forward with our cutting-edge research, reading, planning experiments, analyzing data, and drafting new grant proposals as we telecommute. Introduction Video by Dr. Karl Csaky, CEO – April 9, 2020 Clinical Research in Age-Related Macular Degeneration – April 10, 2020 Investigating […]
READ MOREDrew Brees, Super Bowl-winning quarterback for the New Orleans Saints and Texas native, will be the featured speaker for the 2020 Visionary Luncheon benefiting the Retina Foundation of the Southwest on Wednesday, March 4, 2020. As much pride as Brees takes in his on-field performance as one of the greatest quarterbacks of all time, he takes even […]
READ MOREThe Retina Foundation of the Southwest is one of four U.S. centers conducting a Phase 1/2 dose escalation, gene replacement trial for x-linked retinitis pigmentosa (XLRP). On September 26th, the clinical trial sponsor, Applied Genetic Technologies Corporation (AGTC) announced the initial results. Investigators from all four research sites have begun seeing encouraging signs of benefit […]
READ MORERuvanthi Kularatne, Ph.D., is a Postdoctoral Fellow at the Retina Foundation of the Southwest, working under the direction of Karl Csaky, M.D., Ph.D., Managing & Medical Director. Dr. Kularatne has spent the past year evaluating the effectiveness of therapeutic drugs, and their impact on treatment for age-related macular degeneration (AMD). Currently, our researchers are working […]
READ MOREWe are pleased to announce Krista Kelly, Ph.D. as Director of the Vision and Neurodevelopment Laboratory! Dr. Krista Kelly received her Ph.D. from York University in 2014 before joining the Retina Foundation of the Southwest as a Postdoctoral Fellow in the Crystal Charity Ball Pediatric Vision Laboratory. She is now transitioning into a new role […]
READ MOREAge-related macular degeneration (AMD) has multiple stages of progression. The “dry” form is characterized by yellow deposits called drusen, that grow in size and number, leading to dimmed or distorted vision. There are currently no treatments for dry AMD. When AMD progresses to neovascular AMD, commonly known as “wet” AMD, abnormalities cause new blood vessels […]
READ MOREThe Retina Foundation is an international leader in research on lazy eye, the most common cause of visual impairment in children. A new treatment we are working on in collaboration with Mayo Clinic has the goal of improving the standard treatment of eye patching for children with lazy eye. We are enrolling children who are […]
READ MOREIn a clinical research study headed by Dr. David Birch, scientists in the Rose-Silverthorne Retinal Degenerations Lab are testing the efficacy of gene therapy in patients with choroideremia. This late stage trial is based on early Phase 1 studies where over 90% of treated patients maintained or improved their vision over a one-year follow-up period. […]
READ MOREYi-Zhong Wang, Ph.D., Scientific Director, Macular Function Laboratory, is working to achieve automatic and accurate identification of defects in the structure of patients’ retinas by applying deep machine learning method. Over the past year, using a cutting-edge computer system, Dr. Wang has been training a deep convolutional neural network model to learn how to detect […]
READ MORE